| Assessment Status | Assessment process complete. |
| HTA ID | - |
| Drug | Human alpha1-proteinase inhibitor (A1PI) |
| Brand | Prolastin® |
| Indication | For long-term augmentation therapy in subjects with alpha1-proteinase inhibitor deficiency (phenotypes PiZZ, PiZ(null), Pi (null,null) and PiSZ) within the limits of moderate airflow obstruction (FEV1 35-60%) and the evaluation of the clinical condition (disability). |
| Assessment Process | |
| Rapid review commissioned | 05/05/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended at the Submitted Price. |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.